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found to be of methodologically and clinically reliable 
content. The conclusion of this publication in favor of 
systemic therapy for LNRD received strong consent from 
the consensus conference. Conclusions: The literature 
search strategy using PICO questions helped to achieve 
a fast and standardized selection of publications. The 
recommendation concerning systemic treatment of 
LNRD was first implemented in the update of the Ger-
man Breast Cancer guideline.
© 2018 S. Karger GmbH, Freiburg
Introduction
Breast cancer continues to be the most frequent cancer among 
women. In Germany for example, in 2013, 72,000 cases were re-
ported and almost 18,000 patients died [1]. The treatment of breast 
cancer is an interdisciplinary approach involving among others gy-
necologists, senologists, oncologists and radiologists. Clinical 
guidelines can improve decision making concerning appropriate 
care. The guidance reflects the current state of scientific research 
and expert knowledge assessed by a systematic approach. 
In Germany, the Guideline Program in Oncology (Leitlinien-
programm Onkologie) fosters the development, implementation 
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Summary
Purpose:Our aim was to implement a structured litera-
ture search using PICO (patient/intervention/comparison/
outcome) questions and a standardized consensus 
method for the German Guideline ‘Detection, diagnos-
tics, therapy and follow-up of Breast Cancer’ using, as an 
example, the significance of systemic therapy in lymph 
node recurrent disease (LNRD). Methods: We defined 
specified PICO questions according to the clinical signifi-
cance of a recommendation for systemic therapies in lo-
coregional LNRD. A methodologist performed a system-
atic literature search including randomized controlled 
trials, systematic reviews and observational studies 
(2007–2016). In a consensus conference, the level of evi-
dence and consensus was determined and the clinical 
recommendation was adopted. Results: In total 143 pub-
lications were identified according to the search strategy 
including 14 duplicates, which were excluded. 4 publica-
tions were included based on experts’ choice. The team 
excluded 119 publications, leaving 14 that were then 
screened by a full text search. Finally, 1 publication was 
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and evaluation of evidence-based clinical oncological guidelines. 
The program was initiated by the Association of Scientific Medical 
Societies (AWMF), the German Cancer Association (DKG) and 
the German Cancer Aid (DKH) in 2008. The guideline ‘Detection, 
Diagnosis, Therapy, and Follow-Up of Breast Cancer’ is classified 
as level S3 according to the AWMF Guidance Manual and Rules 
[2]. This level is the highest (out of 3: S1, S2 (S2k, S2e), S3) and 
represents an evidence- and consensus-based approach: a repre-
sentative committee, systematic review and accrual of evidence and 
a structured consensus development. The German Society of Gy-
necology and Obstetrics (DGGG) and the German Cancer Society 
(DKG) update the version every 5 years. The development or up-
dating of guidelines is a work-, time-, and cost-intensive process, 
which requires a sensible utilization of the available resources. 
Most of the statements and recommendations of the German 
breast cancer guideline were revised based on recommendations of 
existing guidelines, which were systematically searched and re-
viewed with the AGREE II instrument [3]. Guidelines were consid-
ered qualitatively eligible if domain 3 (Rigor of development) was 
assessed with > 50%. Moreover, we carried out a systematic search 
and accrual of evidence from systematic reviews, clinical trials or 
observational studies for 17 recommendations, 1 of which focused 
on systemic therapy of recurrent breast cancer. 
The recurrence risk after primary breast cancer varies depend-
ing on tumor size, tumor biology and tumor treatment. In 10–20% 
of cases, recurrence occurs in isolated locoregional sites [4]. Be-
sides local surgery to remove all tumorous lesions and radiother-
apy, there is still need for recommendations concerning systemic 
therapy in lymph node recurrent disease (LNRD). In the following, 
we illustrate the applied methodology for identification, selection, 
appraisal of evidence from systematic reviews and individual stud-
ies and the agreement on recommendations for the current S3 
guideline for breast cancer. 
Methods
Systematic Search and Selection
The methodology to update the evidence- and consensus-based S3 guideline 
for breast cancer is in accordance with the AWMF Manual Guidance and Rules 
as mentioned above. The DGGG and DKG designated a co-ordination and pro-
ject team to steer the process, and a multi-professional expert panel was set up.
We defined research questions based on PICO (patient/ population, inter-
vention, comparison (treatment), outcome) criteria according to the clinical 
significance of a recommendation for systemic therapies in LNRD [5]. The key 
question comprised whether the treatment of breast cancer patients (initial di-
agnosis pN0-pN+) with ipsilateral, supraclavicular and even contralateral lymph 
node disease with systemic therapies (chemotherapy/endocrine therapy) is su-
perior to operation and/or radiation with respect to progression-free survival 
(PFS), overall survival (OS) and quality of life (QoL). The population was de-
fined as breast cancer patients (female/male) with recurrent lympho-regional 
disease or contralateral recurrent disease independent of prior therapies with-
out further distant metastases. Interventions were characterized as endocrine 
therapy in the case of endocrine responsive recurrent disease, chemotherapy or 
goal-directed therapies according to the tumor profile. Additionally, surgical 
resections were included if technically feasible. Outcomes were defined as lo-
coregional recurrence, PFS, OS, QoL and acute and late-onset toxicities. The 
search was restricted to systematic reviews and meta-analyses, randomized con-
trolled trials (RCTs) and observational studies. Search filters from the Scottish 
Intercollegiate Guideline Network (SIGN) were used to restrict the results to 
systematic reviews and meta-analysis or RCTs. Only publications in the English 
or German language, published between 2007 and ‘current’ (i.e. date of search 
carried out (29 June 2016)) were eligible. Inclusion and exclusion criteria were 
derived from the PICO criteria (table 1). 
The search was carried out on 29 June 2016 in the electronic databases Med-
line (via Ovid), Cochrane Database of Systematic Reviews (CDSR), Cochrane 
Centre Register of Controlled Trials (CENTRAL) (via Cochrane Library), Data-
base of Abstracts of Reviews of Effects (DARE) (via Pub Med Health) (table 2) 
and clinical trial registries (clinicaltrial.gov and EU clinical trials registry). The 
working group searched for additional publications, which were included into 
the literature search process if marked as an expert contribution. 
Table 1. Inclusion and exclusion criteria
Inclusion criteria
E1: target group/topic population/topic as described in PICO criteria/
key question
E2: publication type systematic review and meta-analysis, RCT,  
observational studies
E3: search period 2007–current (29.06.2016)
E4: languages German or English
E5: Intervention intervention as described in PICO criteria
E6: Compare control treatment as described in PICO criteria
Exclusion criteria
A1 different target group or topic (i.e. different 
disease) 
A2 different intervention 
A3 different control treatment
A4 different outcome
A5 different publication type (i.e. narrative review, 
editorial, letter, case report etc.)
A6 double publication or more up-to-date  
publication is available of this study 
PICO = patient/intervention/comparison/outcome, RCT = randomized  
controlled trial.
Table 2. Search strategy for RCTs
Ovid MEDLINE(R) 1946 – June week 3 2016
# searches Results, n
 1 breast neoplasms/ or carcinoma, ductal, breast/ 
or breast neoplasms, male/ or inflammatory 
breast neoplasms/
243,771 
 2 breast/ or mammary glands, human/ or nipples/ 
or breast diseases/
47,854 
 3 neoplasms/ or adenocarcinoma/ or carcinoma/ 566,366 
 4 2 and 3 4,658 
 5 (brca or (breast adj4 (adenocarcinoma* or  
cancer* or carcinoma* or metasta* or neoplasm* 
or tumo?r))).ti,ab,kw.
230,787 
 6 1 or 4 or 5 292,026 
 7 neoplasms, second primary/ or neoplasm  
recurrence, local/ or clavicle/ or recurrence/ or 
axilla/ or lymph nodes/ or lymphatic metastasis/
398,574 
Table 2. Continued on next page
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Data Extraction and Critical Appraisal
We downloaded the references of the search hits to Endnote reference 
manager. After removal of duplicates, we extracted information from the re-
maining references (i.e. author, year, journal, title, abstract, DOI number) to 
an Excel sheet and sent it to 2 independent raters for screening. The inde-
pendent raters (2 senological gynecologists) were asked to assess the abstracts 
or titles of each publication for relevance according to the PICO criteria. The 
completed Excel sheets were sent back to the methodologist. Disagreements 
amongst raters were resolved by discussion or consultation with a third per-
son. For the remaining publications, the full-text was obtained and screened 
for eligibility by 2 raters. Disagreement on relevance of the study according to 
the inclusion criteria was again resolved by discussion or by a third person. 
The final set of eligible studies was critically appraised using the SIGN check-
list (Version March 2004) by 2 independent methodologists, and a level of evi-
dence (LoE) (using the system of the Oxford Centre for evidence-based medi-
cine Version 9) was assigned. If there were methodological constraints, the 
LoE was downgraded. Relevant data of the publications were extracted by a 
methodologist and presented in an evidence table to the working group 
(fig. 1).
Guideline Recommendation and Consensus Conference
In a first step, based on the study results, a recommendation draft for the 
consensus conference was formulated by the members of the locoregional re-
currence working group on the S3 guideline. The working group discussed the 
draft during a phone conference moderated by a methodologist of the Guide-
line Program in Oncology. Finally, the strength of recommendation for the 
clinical recommendation was assessed in the final consensus conference of all 
members of the S3 guideline for breast cancer. The strength of recommenda-
tion was determined in relation to the level of evidence of the study by the 
whole guideline committee. The final clinical recommendation and the under-
lying level of evidence and strength of recommendation was then acquiesced by 
elective representatives of participating medical societies in a nominal group 
process moderated by a methodologist of the AWMF. All guideline members 
had to disclose their conflicts of interests to participate in the S3 guideline 
working process. In case of a relevant conflict of interest of elective members, 
they were excluded from the respective vote. The vote was carried out anony-
Ovid MEDLINE(R) 1946 – June week 3 2016
# searches Results, n
 8 ((ipsilateral or contralateral or supraclavicular 
or internal mamma*) adj3 (lymph* or lymph 
nod* or metasta*)).ti,ab,kw.
3,035 
 9 7 and 8 1,893 
10 6 and 9 755 
11 limit 10 to yr=”2007 -Current” 243 
12 limit 11 to English 221 
13 limit 11 to German 1 
14 12 or 13 222 
15 meta-analysis as topic/ 15,079 
16 meta analy$.tw. 77,761 
17 metaanaly$.tw. 1,478 
18 meta-analysis/ 67,381 
19 (systematic adj (review$1 or overview$1)).tw. 66,759 
20 exp review literature as topic/ 8,751 
21 or/15-20 147,447 
22 cochrane.ab. 37,164 
23 embase.ab. 37,303 
24 (psychlit or psyclit).ab. 860 
25 (psychinfo or psycinfo).ab. 8,847 
26 (cinahl or cinhal).ab. 12,363 
27 science citation index.ab. 2,181 
28 bids.ab. 365 
29 cancerlit.ab. 583 
30 or/22-29 58,270 
31 reference list$.ab. 11,064 
32 bibliograph$.ab. 12,096 
33 hand-search$.ab. 4,248 
34 relevant journals.ab. 810 
35 manual search$.ab. 2,587 
36 or/31-35 27,613 
37 selection criteria.ab. 21,706 
38 data extraction.ab. 10,978 
39 37 or 38 30,920 
40 review/ 2,069,843 
41 39 and 40 22,094 
42 comment/ 632,631 
43 letter/ 891,703 
44 editorial/ 383,062 
45 animal/ 5,900,585 
46 human/ 16,091,919 
47 45 not (45 and 46) 4,233,089 
48 or/42-44,47 5,584,098 
49 21 or 30 or 36 or 41 176,114 
50 49 not 48 165,204 
51 14 and 50 11 
aStrategy was adapted according to publication type and electronic database). 
This table demonstrates the search filters for the evaluation of the PICO question. 
RCT = randomized controlled trial, PICO = patient/intervention/comparison/
outcome, Adj4 = adjacency searching helps to find the phrase within 4 words, 
Ti = term searched for in the title of the article, Ab = term searched in the ab-
stract of the article, Tw = textword index includes title and abstract, Kw = term 
searched in the keywords, ? = used to replace zero or one character, * = search 
anything with the stem of the search term, $ = alternative to indicate truncation, 
Or = to combine specific search lines, And = to combine specific search lines, / 
= indicates a subject heading.
Fig. 1. Flow chart demonstrates the selection process of the literature search.
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mously using a TED-transmitter system. The results of all votes were classified 
according to the percentage consensus into: strong consensus, > 95% approval; 
consensus, > 75–95% approval; majority consensus, > 50–75%; and disagree-
ment, < 50% approval. 
Results
According to our search strategy we retrieved 143 publications 
from the databases and clinical trial registries. After removing 14 
duplicates and adding 4 expert contributions, 133 publications 
were screened on an abstract or title level by independent raters 
using predefined exclusion criteria. 119 publications were labeled 
irrelevant according to the PICO criteria. The full texts of the re-
maining 14 publications were retrieved and screened by 2 inde-
pendent experts. 9 of these were excluded since they did not ad-
dress the target group. Wang et al. [6] performed a retrospective 
analysis in a Chinese cohort of patients with contralateral axillary 
lymph node metastasis examined between 1999 and 2008. They 
showed that PFS was increased in patients who were treated with 
radiotherapy. Regarding the manuscript, only 25 patients with re-
current disease were analyzed retrospectively and the PICO ques-
tion was not addressed since a comparison of treatment options 
was not possible. Another publication by Chen et al. [7]. described 
the frequency and risk factors of internal mammary lymph node 
(ILMN) recurrence. The group stated that the hormone receptor 
status is a prognostic factor for OS after ILMN recurrence but also 
did not answer our PICO question The work of Fulga et al. [8] re-
ceived no consideration since they focused on describing the path-
ological characteristics of locoregional recurrence rather than com-
parison of the influence of different treatments on the outcome. 
Both Lanitis et al. [9] and Chang et al. [10] analyzed axillary meta-
static disease or synchronous ipsilateral supraclavicular lymph 
node metastases as primary diagnosis rather than recurrence after 
the primary diagnosis of breast cancer. Ohsumi et al. [11] de-
scribed the detection of ipsilateral regional lymph node recurrence 
using positron emission tomography-computed tomography. 
Moossdorff et al. [12] reviewed the literature to determine the 
prognosis after contralateral lymph node recurrence in breast can-
cer. They stated that locoregional and systemic treatment led to 
incomparable outcome with distant metastases and thus should be 
regarded as a regional event. Van Wely et al. [13] also did not meet 
the PICO question since they published a mini review showing the 
association between lower rates of local recurrence and external 
beam radiation after negative sentinel lymph node detection. Kaur 
et al. [14] reported that remapping of lymph nodes after prior com-
pletion of axillary lymph node dissection is feasible and should be 
considered regardless of the number of initially removed lymph 
nodes. Although these results are interesting for the management 
of recurrent disease, they still do not answer our question concern-
ing a comparison of the treatment options in LNRD. 
Three further publications focused on interventions other than 
those defined by the PICO question. An intriguing study published 
in 2010 by Fan et al. [15] compared metachronous and synchro-
nous manifestations of recurrent disease, but did not systematically 
analyze differences between systemic treatment and regional treat-
ment. Braunstein et al. [16] evaluated the influence of tumor sub-
type on the outcome of locoregional recurrent breast cancer. In 
this study 90% of patients with recurrent disease received surgical 
treatment, 11% radiotherapy, 37% chemotherapy and 28% endo-
crine therapy. Patients with recurrent disease and luminal A-type 
tumors were associated with better disease-free survival (DFS) and 
OS than those with triple-negative tumors. In the univariate analy-
sis they found that surgical intervention improved DFS and inter-
estingly the application of chemotherapy led to worse DFS, while 
radiotherapy and endocrine therapy did not influence the out-
come. In 2011, Pedersen et al. [17] also examined the influences of 
different salvage therapies on the outcome in recurrent disease: 
19% of the patients were operated to an at least macroscopic tu-
mor-free status, 33% received radiotherapy, 40% endocrine ther-
apy and 45% any type of systemic chemotherapy. In summary, 26% 
of all patients had combined regional and systemic treatment. An-
other consensus classification report evaluated publications de-
scribing various methodology and was thus excluded [18]. 
Finally, 1 publication was eligible. The open-label, randomized 
trial examined chemotherapy for isolated locoregional recurrence 
of breast cancer (CALOR) and was published in 2014 [19]. 162 pa-
tients with isolated locoregional recurrences after unilateral breast 
cancer and after primary treatment with mastectomy or lumpec-
tomy were included. The median age was 56 years. Most of the pa-
tients were diagnosed with recurrent disease of the breast (n = 89; 
54.9%) and the chest wall or scar (n = 53; 32.7%), while 20 patients 
(12.3%) had LNRD. Absence of metastatic disease, other malignan-
cies prior to breast cancer and macroscopic clear margins after sur-
gery for recurrent disease were inclusion criteria. Radiotherapy was 
recommended for all patients, while endocrine therapy was recom-
mended for all hormone receptor (HR)-positive patients. The ran-
domized allocation of systemic chemotherapy resulted in 2 groups 
(chemotherapy and no chemotherapy). The type of chemotherapy 
was administered according to physician‘s choice. DFS was set as 
primary endpoint, while secondary endpoint was OS. The median 
follow-up comprised 4.9 years. 80 patients (49.4%) received chem-
otherapy and 94% of patients with HR-positive breast cancer re-
ceived endocrine therapy. As 1 of the major findings, Aebi et al. 
[19] showed that the application of chemotherapy led to a signifi-
cantly improved DFS (69% vs. 57%; hazard ratio 0.59), a reduction 
of distant and local failures and significantly improved OS (88% vs. 
75%; hazard ratio 0.41). Due to methodological constraints, the 
methodologists proposed downgrading the level of evidence from 
1b to 2a according to the Oxford Centre for evidence-based medi-
cine Version 9. These constraints included no blinding, broad 95% 
confidence intervals, and no information about how many patients 
dropped out.
The team of gynecologists then prepared the clinical recommen-
dation based on the literature assessment, which read: ‘Systemic 
therapy after R0 resection of recurrent disease has to be recom-
mended in order to achieve longer disease-free survival as well as 
overall survival’. There was strong consent for the recommendation 
among the voting participants of the consensus conference [20]. 
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Discussion
The evidence-based methods using a predefined question (i.e. 
PICO criteria), a systematic search of the literature and an ap-
praisal of the identified publications are a necessary tool to guaran-
tee high quality, transparency and acceptance of the recommenda-
tions of the S3 guideline for breast cancer. In this work, we demon-
strate a well-structured search strategy to gain evidence for clinical 
guideline recommendations using as an example the systemic 
therapy in lymph node recurrent breast cancer. The search strategy 
helped to filter relevant publications that were precisely screened 
concerning their medical contents. It helped us to discuss the cur-
rent literature and to draft a clinical recommendation. 
After the exclusion of unsuitable publications, only 1 study was 
considered as being of sufficient value to be the source of a clinical 
recommendation. The trial of Aebi et al. [19] perfectly matched 
our PICO question; however, there were methodological con-
straints. Those included the lack of HER2 testing, a short follow-up 
period, missing information on the drop-out rate, a broad 95% 
confidence interval and a study enrolment that did not reach the 
power of 80%. Additionally, our central interest focused on the 
subgroup of patients who develop LNRD. In the CALOR trial, only 
20 patients were diagnosed with LNRD, while most of the patients 
(n = 142) were diagnosed with chest wall, scar or breast recurrent 
disease. These concerns led to a downgrading of the level of evi-
dence from 1b to 2a. Moreover, efficacy of chemotherapeutic treat-
ment was predominant in cases of HR-negative tumors. In cases of 
HR-positive tumors, benefit could not be excluded and remains 
unclear based on the current data. In the retrospective study of 
Pedersen et al. [17] combined locoregional and systemic therapy 
were associated with longer PFS and OS compared to systemic or 
locoregional therapy alone. Even though the data were not rand-
omized and chemotherapeutic regimens were not up to date, the 
results were in line with the CALOR trial. In contrast to those re-
sults, Braunstein et al. [16] showed that the application of chemo-
therapy led to worse outcome, while radiotherapy and endocrine 
therapy had no influence on the outcome. The authors suggested 
that the underpowered design on the one hand and the mainly HR-
positive patients in their collective on the other hand led to this di-
vergence of results. There is no doubt that histopathological exami-
nation using biopsies plays a crucial role for the management of 
recurrent disease and should be considered first before a therapeu-
tic strategy is set up. Despite the lack of more methodically valua-
ble publications, we were able to draft a recommendation that 
should be considered in systemic therapy in cases with recurrent 
breast cancer. 
This recommendation is in line with the European Society of 
Medical Oncology (ESMO). EMSO stated in their third updated 
consensus guideline in February 2017 that, in the absence of dis-
tant metastases, the use of systemic therapy (chemotherapy, endo-
crine therapy and/ or anti-HER2-directed therapy) should be con-
sidered in addition to local therapy (surgery and/or radiation ther-
apy). In comparison to our recommendation, the evidence level is 
1b. The ESMO guideline, however, was not considered since the 
methodological evaluation of domain 3 according to the AGREE II 
instrument was below 50%. Since 2010, the American Society of 
Oncology (ASCO) uses a formal consensus methodology, includ-
ing quality appraisal, to rate the strength of evidence and the 
strength of recommendation [21]. In these aspects, the strategy of 
ASCO and AWMF are quite similar. So far, no ASCO guidelines 
have been published that give their view on systemic treatment of 
lymph node recurrent breast cancer. 
There are several benefits, but also limitations, of the presented 
search strategy. Methodical constraints might relate to the time 
limitation of 16  years (2000–2016) of the inspected publications. 
Moreover, only publications in English and German were in-
cluded; however, it might be reasonably assumed that most of the 
relevant methodical and high-valued publications are in English. A 
benefit of the strategy is that it represents a quick search especially 
tailored to filter all the relevant publications to answer the clinical 
question. Furthermore, inclusion and exclusion criteria were pre-
defined before the search was carried out. Another strength is the 
gradually performed screening of the literature by senological gy-
necologists and the standardized consensus conference to guaran-
tee a high standard of medical and methodical content. 
In summary, we believe that the presented search strategy and 
methodology is important and should be considered when clinical 
guidelines are set up. Further investigations are required to sub-
stantiate the clinical recommendation made. 
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